Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines

{
  "signal_id": "050da627-8490-d92b-629d-bbca1055c789",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-08-27T20:01:57+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "url": "https://www.ncnewsonline.com/news/national/moderna-receives-u-s-fda-approval-for-updated-2026-2027-covid-19-vaccines/article_62630cbf-e79e-5f58-a3f4-512ee94bca9f.html",
    "title": "Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines - New Castle News",
    "excerpt": "CAMBRIDGE, MA / ACCESS Newswire / August 27, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19. The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. mNEXSPIKE, Moderna's latest COVID-19 vaccine, is approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. Story continues below video Copyright 2026 ACCESS Newswire. All Rights Reserved. Log In Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language. PLEASE TURN OFF YOUR CAPS LOCK. Don't Threaten. Threats of harming another person will not be tolerated. Be Truthful. Don't knowingly lie about anyone or anything. Be Nice. No racism, sexism or any sort of -ism that is degrading to another person. Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts...",
    "product": "mNEXSPIKE",
    "summary": "Moderna received U.S. FDA approval for its new 2026-2027 COVID-19 vaccine, mNEXSPIKE.",
    "location": "Cambridge, MA, USA",
    "planning": false,
    "image_url": "https://bloximages.chicago2.vip.townnews.com/ncnewsonline.com/content/tncms/assets/v3/editorial/8/57/8572dad2-5c6f-563c-b5a3-04d9208733a4/6a909f592e790.image.jpg?crop=277%2C277%2C461%2C0&resize=200%2C200&order=crop%2Cresize",
    "confidence": 0.95,
    "product_data": {
      "name": "mNEXSPIKE",
      "full_text": "mNEXSPIKE® (COVID-19 Vaccine, mRNA)",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-08-27T20:01:57Z",
    "location_data": [
      {
        "city": "Cambridge",
        "state": "Massachusetts",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-08-27",
    "article_sentence": "Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax® (COVID-19 Vaccine, mRNA) and mNEXSPIKE® (COVID-19 Vaccine, mRNA), containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19."
  }
}

curl https://signals.autobound.ai/v1/signals/050da627-8490-d92b-629d-bbca1055c789 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"modernatx.com","limit":20}'